SV Health Investors

#InternationalDayofWomenandGirlsinScience provides the perfect opportunity to celebrate the female leaders in the SV portfolio.   Diversity, equity and inclusion is important to SV and we are proud of the female representation we have across the portfolio which outperforms life sciences VC benchmarks. 40% of companies within the SV Therapeutics portfolio are led by female CEOs and 90% have female C-suite members.   We still have some way to go before we reach parity however, so we have asked some of the female CEO’s within our portfolio to provide their top tips to women, girls and anyone else looking to become scientific leaders. Thank you to Jane Osbourn OBE of Alchemab Therapeutics Ltd, Jane Rhodes of AstronauTx, Lisa Deschamps of AviadoBio, Joanna Wolak of Endlyz UK Limited, Irene Griswold-Prenner of Nitrase Therapeutics, Shelley Force Aldred of Rondo Therapeutics, Tara Nickerson of Therini Bio, Inc. and Nicki Thompson of TRIMTECH Therapeutics Limited for doing so.

We are excited to announce that SV Health Investors portfolio company AdvanCell has announced an expansion to the scope and breadth of its collaboration with Eli Lilly and Company with the aim of delivering innovative cancer therapies to patients.

SV Health Investors is excited to share that Luke Johnson will be joining the SV Growth-Buyout team as an Operating Partner, focused on portfolio value creation and new platform execution. Luke is an experienced executive with operational expertise across the medical device landscape, including in contract design & development, manufacturing, and OEM products. Luke brings a depth of knowledge as a multi-time CEO and commercial leader, and is currently Chairman of SV portfolio company Robling Medical, LLC

I look forward to connecting with everyone at LSI this year!

On #WorldCancerDay we are delighted to take this opportunity to recognise the innovative biotech companies within the SV portfolio developing cutting edge oncology therapies. Cancer is among the leading causes of death worldwide with almost 20 million new cases and 9.7 million cancer-related deaths worldwide in 2022. The novel therapeutics being developed by SV portfolio companies have the potential to shape the future of cancer treatment and change the lives of patients AdvanCell Artios Bicycle Therapeutics Enara Bio Mestag Therapeutics Nimbus Therapeutics Ribometrix Inc. Rondo Therapeutics Xilio Therapeutics, Inc.

SV is delighted to have co-led AdvanCell’s oversubscribed $112m Series C financing alongside Sanofi Ventures, Abingworth, and SymBiosis. As part of the financing, Jamil M. Beg has joined the Company’s Board. https://lnkd.in/evMtyxwF

We are excited to announce that SV Health Investors portfolio company Doctors of Physical Therapy is partnering with Empower Physical Therapy Group!

SV Health Investors' Dementia Discovery Fund (DDF) portfolio company, Harness Therapeutics, has appointed Dr Heather Preston as its Chair. The Company has also raised further funding including from new investor Ono Ventures Investment.

Members of the SV Health Investors team are heading to Miami for iConnections Global Alts on January 27th – 30th. Managing Partner Gregory Madden and Director of Investor Relations Dylan Arpey will be in attendance and are looking forward to connecting with fellow #Alternative Investment leaders during the industry-leading event.   Please contact [email protected] in advance of the conference to schedule time with our team. We look forward to seeing you there! #GlobalAltsMiami

Members of the SV Health Investors team are heading to Miami for iConnections Global Alts on January 27th – 30th. Managing Partner Gregory Madden and Director of Investor Relations Dylan Arpey will be in attendance and are looking forward to connecting with fellow #Alternative Investment leaders during the industry-leading event.   Please contact [email protected] in advance of the conference to schedule time with our team. We look forward to seeing you there! #GlobalAltsMiami